The Imagio® breast imaging system – opto-acoustic fused with ultrasound (OA/US) – is currently CE marked in Europe with commercial delivery of the product expected mid-2017.  The Imagio® OA/US breast imaging system is currently being processed through the U.S. FDA system of approval.  That approval is expected early 2018 with sales in the U.S. immediately after approval.